Technology Challenges and Trends in Clinical Trials
Cancer remains a leading cause of death among Americans with nearly two million newly diagnosed patients in 2018. As this trend continues, various cancer treatments are becoming more and more sought after in the fight against this complicated and deadly disease. To that end, the number of clinical trials is on the rise as are the challenges that stem from so much competition.
When biotech and pharma companies seek out facilities to run their clinical trials, the options may seem overwhelming and there is a lot to consider. In a recent article published by Fierce Biotech, Stephen Gately, PhD, Chief Executive Officer of TD2, has identified a few factors that make one facility stand out over another, such as the role of new technologies in the clinical trial process and how facilities are leveraging them.
Sites that are innovative in the way they analyze and use patient data are seeing great success, especially through new technologies in the clinical space such as Artificial Intelligence (AI). However, most sites aren’t at the stage to utilize these new technologies and human involvement is still necessary in one capacity or another in order to keep this data up to date. Those who are specialized and can maximize efficiency during the process have a leg up over the competition. In addition, clinical trial payment and big data analytics are trending technologies as well as patient engagement solutions, which include mobile health and electronic health records where adoption rates are around 60 percent.
There is a lot more to consider when it comes to competition in the clinical trial space – operational challenges, site selection, patient enrollment, and the research process timeline are just a few things to keep in mind when embarking on a new clinical trial. To learn more about TD2’s approach on planning a successful oncology clinical trial and how to design a study with the end goal in mind, read the full article here.
You may also be interested in
About Translational Drug Development (TD2)
TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit TD2inc.com.